

Prognostic value of the oxygenation index measured during mechanical ventilation and weaning. A retrospective cohort study

Esra Eriş,¹ Ayshan Mammadova,² Ayşe Taşçı Kara,² Aydın Atasoy,¹ Zeynep Sena Solmaz,¹ Gül Gürsel^{1,2}

¹Critical Care Fellowship Program, Gazi University School of Medicine, Ankara; ²Department of Pulmonary Critical Care Medicine, Gazi University School of Medicine, Ankara, Turkey

Correspondence: Esra Eriş, Critical Care Fellowship Program, Gazi University School of Medicine, Ankara.
Tel.: +90 03122022000; Fax: +90 0312 221 32 02.
E-mail: e.kurtulgu@gmail.com

Key words: mechanical ventilation, respiratory failure, intensive care unit, ROX index, oxygenation index.

Contributions: EE, GG, designed and coordinated the study, participated in data acquisition and interpretation, and drafted the article; ZSS, AM, ATK, AA, participated in data collection. EE, AM, GG, participated in the interpretation of the data. All authors critically reviewed the article for important intellectual content and approved the final version.

Conflict of interest: the authors declare no potential conflicts of interest.

Ethics approval and consent to participate: this study was approved by the Gazi University Clinical Research Ethics Committee (date: 14.06.2021; decision No: 546).

Informed consent: all written consents are obtained from the patients' relatives during hospitalization and are available in the patients' hospitalization files.

Patient consent for publication: not applicable, as this study does not contain any individual patient data.

Availability of data and materials: this single-centre retrospective cohort study of 107 patients was carried out by Gazi University Faculty of Medicine, Department of Pulmonary Critical Care Medicine. Upon reasonable request, data is available at this address.

Funding: this research received no specific grant from public, commercial, or non-profit funding agencies.

Received: 2 November 2023.

Accepted: 30 April 2024.

Early view: 23 July 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2025; 95:2840

doi: 10.4081/monaldi.2024.2840

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

This study aimed to investigate the predictive value of the ratio of oxygen saturation (ROX) index calculated during mechanical ventilation (MV) and the weaning period in evaluating readiness to wean and the success of the spontaneous breathing trial (SBT), extubation, and mortality. We also compared the results of the ROX index calculated with partial arterial oxygen pressure (PaO₂), arterial oxygen saturation (SaO₂%), and probe oxygen saturation (SpO₂%). In this retrospective cohort study, the ROX index was calculated by SpO₂%, PaO₂, and SaO₂% separately using the ROX index formula (PaO₂ or SaO₂ or SpO₂ /FiO₂)/respiratory rate. ROX was calculated during the first 3 days of MV treatment and the weaning period daily (SBT). Positive end-expiratory pressure and peak inspiratory pressure values were also recorded during these measurements. These ROX values were used to analyze whether they predict weaning readiness, SBT, extubation failure (EF), and mortality.

The study included 107 mechanically ventilated patients. Weaning could be tried in 64 (60%) of the 107 patients; 44 (69%) of the 64 patients succeeded, and extubation was performed. 19 (43%) of 44 patients had EF. ROX values calculated with PaO₂ during MV and SBT predicted readiness to wean, EF, and mortality better than ROX values calculated with SaO₂ and SpO₂. ROX values calculated with PaO₂ during the third day of MV had the highest sensitivity and specificity for EF (sensitivity: 81%, specificity: 70% for the ROX<11 value).

The results of this study suggest that the calculation of the ROX index, not only with SpO₂% but also with arterial blood gas PaO₂ and SaO₂% values, may be helpful in predicting the weaning readiness evaluation, SBT, and extubation success and mortality. Further studies with more patients are necessary to verify and standardize these results.

Introduction

Hypoxic respiratory failure is the leading cause of intensive care unit (ICU) admissions and carries a hospital mortality risk of up to 20% [1]. 42% of patients require mechanical ventilation (MV), and 14 % face weaning or extubation failure (EF) [1,2].

There are different oxygenation indices to evaluate the severity of the deterioration in oxygenation of patients, and the most commonly used one is PaO₂/FiO₂, which is the ratio of the oxygen partial pressure in arterial blood gas (PaO₂) of the patient to the fraction of inspired oxygen (FiO₂). PaO₂/FiO₂ is one of the most important methods to evaluate respiratory function and degree of hypoxia in critically ill patients [3,4]. The ratio of oxygen saturation

(ROX) index $[(\%SpO_2(\text{Oxygen saturation})/FiO_2)/\text{respiratory rate (RR)}]$ has been intensively studied in recent years. The ROX index has been evaluated extensively to evaluate intubation indication, especially during high-flow nasal oxygen therapy (HFNO) treatment. It has been helpful in patients with non-COVID and COVID-19 pneumonia [5-9].

The original ROX index uses $SpO_2\%$ to calculate PaO_2/FiO_2 since it is practical and readily available. Much data support the similarity and correlation between SpO_2/FiO_2 and PaO_2/FiO_2 [5,8]. On the other hand, in severely ill ICU patients using vasoactive drugs, the PaO_2 -arterial oxygen saturation (SaO_2) or SpO_2 relation may change with the pressure of carbon dioxide ($PaCO_2$) levels, pH, temperature, and 2,3-diphosphoglycerate concentration. Furthermore, pulse oximeter devices can not consider increased methemoglobin or carboxyhemoglobin levels or the interference of jaundice. Therefore, ROX values calculated during MV and weaning with PaO_2 , SaO_2 , and SpO_2 might differ [9-11].

Although MV is such a widely used treatment with frequent complications and high mortality risk, there is still no method with a high diagnostic value that predicts the patient's readiness for weaning, spontaneous breathing trial (SBT) failure, or EF.

Early weaning from MV may impair gas exchange, leading to hypoxemia and hypercapnia, causing reintubation, which increases the risk of nosocomial pneumonia and mortality. On the other hand, delayed weaning leads to an increased risk of complications related to MV, prolonged stay in the ICU, and increased cost. Coplin *et al.* stated that the mortality is 12% when there is no delay in extubation and 27% when extubation is delayed. For this reason, "weaning" should be done as soon as possible at the appropriate time [12,13]. Various clinical and objective weaning readiness (WR) assessment criteria and weaning success predictors have been proposed to increase weaning and extubation success (ES). These predictors include criteria such as PaO_2/FiO_2 or rapid shallow breathing index (RSBI) [14].

On the other hand, RR is essential not only in intubation decisions but also in extubation. Therefore, the ROX index may help predict weaning or ES as it predicts intubation indication. As far as we know, there needs to be data in the literature to evaluate the ROX index as a WR, SBT, or EF predictor.

In this study, we aimed to investigate the predictive value of the ROX index calculated during MV and weaning to evaluate the WR, the success of SBT, extubation, and mortality. We also compared the ROX index results with PaO_2 , $SpO_2\%$, and SaO_2 .

Materials and Methods

This single-center retrospective cohort study of 107 patients was carried out by the Gazi University Faculty of Medicine, Department of Pulmonary Critical Care Medicine, Ankara, Türkiye. The study was approved by the Gazi University Clinical Research Ethics Committee (Date: 14.06.2021, Decision No: 546). All patients admitted to the ICU with a preliminary diagnosis of type 1 and 2 respiratory failure and intubated and mechanically ventilated for at least 4 days between January 1, 2017, and December 31, 2020, were included in the study. Exclusion criteria were patients with do-not-resuscitate orders (DNR) and those who were tracheostomised.

Patients' data from hospitalization until discharge or death were collected from electronic medical records and reviewed. Demographic [age, gender, body mass index (BMI)], medical history (diagnosis, comorbidities, having home oxygen or ventilation treatments), clinical [the acute physiology and chronic health eval-

uation II (APACHE II), sequential organ failure assessment (SOFA) scores, presence of infection sepsis, source of infection, RR, $SpO_2\%$, $FiO_2\%$] laboratory (admission arterial blood gas values), management [noninvasive ventilation treatment before and after MV therapy and their durations, intubation extubation times, and outcome data (if the patient is discharged or has died, readiness to WR or failure of SBT and, extubation)] were obtained from the medical records.

Weaning protocol of our intensive care unit and definitions

Our weaning protocol involves readiness assessments and SBT. To assess WR, we review parameters, including clinical improvement of the cause of respiratory failure, oxygenation and ventilation parameters, mental status, secretions, and cardiovascular stability. These parameters are explained in the definitions part of the methods section.

For SBT, a T-tube trial entails disconnecting the patient from the ventilator and providing additional oxygen. They are extubated if the patient can tolerate SBT for 30-120 minutes. Criteria to define SBT failure: $PaO_2 < 60$ mmHg and $FiO_2 > 0.5$, $SaO_2 < 90\%$ and $FiO_2 > 0.5$, $PaCO_2 > 50$ mmHg or increased by more than eight mmHg, $pH < 7.32$, $RR > 35$ breaths/min or increased by more than 50%, heart rate > 140 bpm or increased by more than 20% systolic blood pressure > 180 mmHg or < 90 mmHg, uncontrollable psychomotor agitation, reduced level of consciousness, excessive sweating and cyanosis evidence of increased respiratory muscle effort. Based on these criteria, the procedure is terminated if a patient can not tolerate an SBT. SBT is reattempted every 24 hours. Following failed SBT, patients receive ventilatory support [15].

Definitions

Regarding WR, patients can be weaned from MV if they meet the following criteria: reduced secretions, having effective cough, hemoglobin > 8 g/dL, adequate oxygenation ($PaO_2/FiO_2 > 150$ mmHg or $SaO_2 > 90\%$ when $FiO_2 < 0.5$), tolerance of pressure support mode (PSV), body temperature $< 38.5^\circ\text{C}$, no need sedatives and vasopressor agents, no acidosis (pH ranging from 7.35 and 7.45), no electrolyte disturbances, adequate fluid balance. If these criteria are met, the SBT is performed [16,17].

SBT success is considered as the end of the SBT period with extubation [17]. Whereas, SBT failure refers to the intolerance of SBT [17].

Successful extubation was defined as no need for reintubation for more than 48 hours, regardless of the need for sequential non-invasive positive pressure ventilation; EF was defined as inevitable reintubation within 48 hours of extubation [18,19]. $SpO_2\%$, PaO_2 , $SaO_2\%$, FiO_2 , and RR values were recorded daily during the first 3 days of MV and SBT.

ROX index was calculated daily using $SpO_2\%$, PaO_2 , and $SaO_2\%$ separately using the ROX index (PaO_2 or SaO_2 or SpO_2/FiO_2)/RR formula. $MVD1PaO_2$, $MVD2PaO_2$, $MVD3PaO_2$ are the index calculated by PaO_2 on the first 3 days of MV of the patient; $MVD1SaO_2$, $MVD2SaO_2$, $MVD3SaO_2$ represents the patient's ROX index calculated with SaO_2 on the first 3 days of MV, and $MVD1SpO_2$, $MVD2SpO_2$, $MVD3SpO_2$ represent the ROX values calculated by the patient's SpO_2 on the first, second and third day of MV.

The first day of weaning was accepted as the day when the patient's hemodynamic and respiratory parameters were stable,

and PSV was tried. Weaning ROX indices were calculated from the values taken during the SBT application in the first trial. ROX indexes were calculated separately for PaO₂, SaO₂%, and SpO₂% (WSBTPaO₂, WSBTSaO₂, WSBTSPO₂). Peak inspiratory pressure (PIP), pressure support, and positive end-expiratory pressure (PEEP) values were also recorded when ROX values were calculated.

According to our ICU's MV protocol, MV was initiated with a tidal volume (VT) of 6 mL/kg of ideal body weight and minimal PEEP titrated with FiO₂ to target oxygen saturation [20,21]. Ventilation adjustments were made daily based on arterial blood gas analysis, and when patients' reasons for intubation and MV stabilized, hemodynamics stabilized, and oxygenation improved, PSV was tried.

Statistical analysis

Variables with normal distributions were presented as mean \pm standard deviation (SD) and were compared by an independent samples *t*-test. For non-normally distributed variables, the Mann-Whitney *U* test was used. Categorical variables were described as percentages and compared using the Chi-squared or Fisher's exact test when appropriate. For WR, SBT, ES, or failure, the ROX values calculated during the first 3 days of MV and the weaning period (SBT) were compared with the Student's *t*-test. The receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off values of the ROX index for WR, SBT, ES, or failure and mortality. Logistic regression analysis was performed for significant parameters in the Student's *t*-test and ROC curve analysis to check whether they were independent risk factors for weaning failure, EF, and mortality. Other factors (sepsis, comorbidities, *etc.*) that may be risk factors for these outcome criteria were also included in this analysis.

Results

A total of 234 patients were screened for the study (Figure 1). When non-intubated, tracheostomised, and DNR-ordered patients were excluded, the remaining 107 patients were included in the study. Tables 1 and 2 summarize the patients' demographics, comorbidities, diagnoses, and clinical and laboratory measurements. 49 (46%) of the patients were smokers, 26 (24%) of them were using home oxygen therapy, and 7 (6.5%) of them were using home MV. Their mean BMI was 29 ± 24 kg/m².

All calculations were made with the worst values recorded during MV (on the first, second, and third day of MV), the WR evaluation period (on the first day of weaning during PSV), and the day of SBT. Of our patient population, 43% had pulmonary comorbidity, and 26% had cardiac comorbidity. Chronic obstructive pulmonary disease exacerbation and pneumonia were the most common admission diagnoses. In our study, MVROX values calculated during the first 7 days of MV were recorded, and we presented the results of the first 3 days because they had significant results. The weaning duration was 7 days; nearly half of the patients were mechanically ventilated for more than 14 days, and 35% of them were ventilated for longer than 21 days. WR was evaluated in 107 (46%) of the patients; 64 (60%) were ready to wean and SBT, and 44 (69%) of them passed the SBT trial and were extubated. EF occurred in 19 (43%) of the extubated patients. Mean \pm SD MV, weaning, and ICU LOS durations were 14 ± 18 , 7 ± 7 , and 17 ± 20 days, respectively (Table 2).

Table 1. Demographics and admission diagnosis.

	n (%) or mean \pm SD
Age, years	69 \pm 17
Gender (female)	47(44%)
GCS	8 \pm 4
APACHE II	25 \pm 8
SOFA score	7 \pm 3
MV SOFA	8 \pm 3
Weaning SOFA	5 \pm 3
SBT SOFA	5 \pm 2
Admission diagnosis	
Pneumonia	62 (58)
Sepsis, septic shock	56 (52)
COPD exacerbation	15 (14)
Neurologic	14 (13)
Congestive heart failure	22 (21)
Acute kidney injury	11 (10)
Venous thromboembolism	8 (8)
Physical examination findings	
Mean arterial pressure, mmHg	83 \pm 18
Heart rate, min-1	102 \pm 23
Respiratory rate, min-1	27 \pm 8
Admission SpO ₂ , %	91 \pm 10
PaO ₂ /FiO ₂ , mmHg	155 \pm 93
Baseline arterial blood gas values	
pH	7.54 \pm 2
PaO ₂ , mmHg	77 \pm 32
PaCO ₂ , mmHg	48 \pm 22
HCO ₃ , mEq	24 \pm 6
SaO ₂ , %	91 \pm 10

SD, standard deviation; GCS, Glasgow coma scale; APACHE II, acute physiologic and chronic health evaluation; MV, mechanical ventilation; SOFA, sequential organ failure score; SBT, spontaneous breathing trial; COPD, chronic obstructive lung disease; SpO₂, probe oxygen saturation; PaO₂/FiO₂, partial arterial oxygen pressure/fraction of inspired oxygen; PaO₂, partial arterial oxygen pressure; PaCO₂, partial arterial carbon dioxide pressure; HCO₃, bicarbonate; SaO₂, arterial oxygen saturation.

Table 2. Parameters related to mechanical ventilation and weaning outcome.

Outcomes of MV	n (%) or mean \pm SD
Readiness to weaning assessment	107/235 (46)
Passed weaning readiness and ready to SBT	64/107 (60)
Extubation failure	19/64 (30)
Durations	
Weaning duration, days	7 \pm 7
MV duration, days	14 \pm 18
ICU time, days	17 \pm 20
Reintubation time, day	7 \pm 7
Mortality rate,%	55 (51)
Duration of MV>7 days>14 days>21 days	Rates (%)634635

SD, standard deviation; MV, mechanical ventilation; SBT, spontaneous breathing trial; ICU, intensive care unit.

Weaning readiness

ROX values calculated with PaO₂, SaO₂% and SpO₂% during the first 3 days of MV were used to evaluate readiness to weaning. MVD1PaO₂, MVD2PaO₂, MVD1SaO₂, MVD2SaO₂, and

MVD1SpO₂, MVD2SpO₂ ROX values calculated in the first 2 days were significantly lower in the not ready to wean (NRW) group than in the WR group. They predicted NRW from the first 2 days of MV with a cut-off point between 8-11, sensitivity between 66% and 71%, and specificity between 52% and 60% (Table 3).

Table 3. Threshold values determined for WR EF and mortality from the ROX values calculated during MV and weaning*.

	AUC	(CI 95%) p	Threshold		Sensitivity (%)	Specificity (%)
WR evaluation						
MVD1PaO ₂	0.655	(0.548-0.762)	0.008	<8	69	60
MVD1SaO ₂	0.669	(0.563-0.774)	0.004	<9	66	60
MVD1SpO ₂	0.667	(0.561-0.772)	0.004	<8	66	55
MVD2PaO ₂	0.664	(0.506-0.773)	0.006	<10	70	59
MVD2SaO ₂	0.655	(0.544-0.766)	0.009	<11	71	52
MVD2SpO ₂	0.664	(0.554-0.774)	0.006	<11	71	52
MVD3PaO ₂	0.762	(0.655-0.868)	0.005	<11	74	67
Weaning SBT						
WSBTSaO ₂	0.728	(0.575-0.880)	0.024	<11	71	60
WSBTSpO ₂	0.741	(0.586-0.895)	0.017	<11	76	60
Extubation						
MVD3PaO ₂	0.801	(0.660-0.943)	0.001	<11	81	70
Mortality						
MVD3PaO ₂	0.740	(0.637-0.843)	0.005	<11	74	66

*Only significant parameters were given; EF, extubation failure; ROX, respiratory rate-oxygenation; MV, mechanical ventilation; WR, weaning readiness; SpO₂, oxygen saturation; PaO₂, partial arterial oxygen pressure; SaO₂, arterial oxygen saturation; SBT, spontaneous breathing trial. MVD1,2,3PaO₂: ROX value calculated with PaO₂ during the first 3 days of MV; MVD1,2SaO₂: ROX value calculated with SaO₂ during the first 2 days of MV; MVD1,2, SpO₂: ROX value calculated with SpO₂ during the first 2 days of MV; WSBTSaO₂: ROX value calculated with SaO₂ during SBT; WSBTSpO₂: ROX value calculated with SpO₂ during SBT.




Figure 1. Flowchart. MV, mechanical ventilation; VACV, volume assist control; PSV, pressure support ventilation; SBT, spontaneous breathing trial.

Among MVD3PaO₂, MVD3SaO₂, and MVD3SpO₂% ROX values, only MVD3PaO₂ was significantly lower in the NRW group than in the RW group (Table 4).

The highest sensitivity and specificity values were obtained with the MVD3PaO₂ value below 11 for NRW (sensitivity: 74%, specificity: 67%). The mean±SD inspiratory and expiratory pressure values recorded during the first 3 days of MV were as follows: PIP (26±7, 25±7, 26±7 mmHg, respectively), and PEEP (6±2, 6±2, 5±2 mmHg, respectively). In the logistic regression analysis, none of these ROX values was found to be an independent risk factor for NRW.

Among ROX values calculated during SBT, only WSBTPaO₂ was not significantly lower in the NRW group than in the RW group (Table 4). WSBTSaO₂ and WSBTSpO₂ are lower than 11 predicted SBT failures, with 71%, 76% sensitivity, and 60% specificity, respectively.

Extubation failure

When we compared ROX values calculated from PaO₂, SaO₂%, and SpO₂% values for the first 3 days of MV and the first day of weaning, MVD1PaO₂ values calculated on the first and third days were significantly lower in the EF group than the ES group (Table 4). In the ROC curve analysis, the cut-off value of 11 for MVD3PaO₂ had the highest sensitivity and specificity values (sensitivity: 81%, specificity: 70%) (Table 3). ROX values calculated during SBT (WSBTPaO₂-SaO₂-SpO₂) were not significantly different between ES and EF groups (Table 4).

Mortality

Among ROX values calculated from PaO₂, SaO₂% and SpO₂% values in the first 3 days of MV and the first day of weaning, MVD2PaO₂, MVD2SaO₂, and MVD2SpO₂ values were not significantly different between the exitus and discharge groups. The significant ROX value for mortality prediction was MVD3PaO₂ (Table 4). The highest sensitivity and specificity values were found for the MVD3PaO₂ cut-off value 11 (sensitivity: 74%, specificity: 66%) (Tables 3 and 4).

Discussion

This study aimed to determine if the ROX index calculated with PaO₂, SaO₂, and SpO₂ during the MV and weaning period can predict WR, SBT, EF, and mortality. Our results suggest that ROX values calculated with PaO₂ during the third day of MV (<11) predicted not to be ready for weaning, SBT failure, EF, and mortality. Additionally, MVD1,2PaO₂, MVD1,2SaO₂, and MVD1,2SpO₂ values (>8) measured during the first 2 days of MV predicted WR with relatively low sensitivity and specificity values. Again, WSBTSaO₂ and WSBTSpO₂ values (>11) predicted SBT success.

In this study, many ROX values calculated during the first 3 days of MV, SBT, and post-extubation periods predicted the weaning and extubation outcomes. The best sensitivity and specificity values to predict RW, EF, and mortality were obtained with ROX values calculated with PaO₂. The original definition of the ROX

Table 4. Comparison of ROX values calculated during the first 3 days of mechanical ventilation and weaning in terms of weaning readiness, spontaneous breathing trial and extubation failure success and mortality.

ROX values calculated during MV (n=107), mean±SD									
ROX values calculated during the day 1-3 with PaO ₂ , SaO ₂ and SpO ₂	Weaning readiness			SBT success and failure groups			Mortality		
	NRW (n=43)	RW (n=64)	p	SBT success (n=44)	SBT failure (n=20)	p	Exitus (n=55)	Discharge (n=52)	p
MVD1PaO ₂	8±5	15±21	0.017	17±24	9±4	0.045	12±20	12±12	0.772
MVD1SaO ₂	9±5	15±18	0.008	17±21	11±5	0.067	11±13	14±16	0.402
MVD1SpO ₂	9±5	15±19	0.009	17±22	11±5	0.068	11±13	14±17	0.386
MVD2PaO ₂	10±5	13±5	0.004	13±6	12±6	0.351	10±5	13±5	0.100
MVD2SaO ₂	11±5	14±5	0.007	14±5	13±5	0.788	12±6	14±5	0.113
MVD2SpO ₂	11±5	15±6	0.005	14±5	14±5	0.998	12±6	14±5	0.143
MVD3PaO ₂	9±6	15±6	0.005	16±5	11±5	0.001	10±7	15±5	0.001
MVD3SaO ₂	13±16	17±12	0.203	16±4	17±20	0.696	15±17	15±4	0.938
MVD3SpO ₂	13±15	17±12	0.204	16±5	18±20	0.601	15±17	15±5	0.974
ROX values calculated during SBT (n=64), mean±SD									
ROX values calculated during SBT with PaO ₂ , SaO ₂ and SpO ₂	SBT success and failure			ES EF			Mortality		
	SBT failure (n=20)	SBT success (n=44)	p	(n=25)	(n=19)	p	Exitus (n=30)	Discharge (n=34)	p
WSBTPaO ₂	11±4	14±5	0.098	14±5	13±5	0.458	12±4	14±5	0.367
WSBTSaO ₂	10±3	14±4	0.020	14±3	12±5	0.274	12±4	14±4	0.131
WSBTSpO ₂	10±3	15±13	0.022	16±15	12±5	0.328	12±4	16±14	0.214

SD, standard deviation; ROX, respiratory rate-oxygenation; WR, weaning readiness; NRW, not ready to wean; SBT, spontaneous breathing trial; ES, extubation success; EF, extubation failure; MV, mechanical ventilation; SpO₂, oxygen saturation; PaO₂, partial arterial oxygen pressure; SaO₂, arterial oxygen saturation. MVD1,2,3PaO₂: ROX value calculated with PaO₂ during the first 3 days of MV; MVD1,2,3SaO₂: ROX value calculated with SaO₂ during the first 3 days of MV; MVD1,2,3SpO₂: ROX value calculated with SpO₂ during the first 3 days of MV; WSBTPaO₂: ROX value calculated with PaO₂ during SBT, WSBTSaO₂: ROX value calculated with SaO₂ during SBT; WSBTSpO₂: ROX value calculated with SpO₂ during SBT.

index uses SpO₂ to calculate a noninvasive measurement for PaO₂/FiO₂ since there is no need for arterial blood sampling data [5]. Additionally, since pulse oximetric measurement of SpO₂/FiO₂ is widely used and validated as a surrogate for PaO₂/FiO₂, SpO₂/FiO₂ can be utilised for diagnosis and assessment of the severity of acute respiratory distress syndrome (ARDS) if SpO₂ is <97% according to the recent American Thoracic Society ARDS definition [22]. On the other hand, in severely ill intensive care patients, the oxyhemoglobin dissociation curve position changes with acidosis and hypercapnia, and these factors influence the PaO₂ and SaO₂ relationship. Moreover, these patients frequently have low blood pressures and higher doses of vasopressor usage, causing lower SpO₂ values than SaO₂; because of all these reasons, ROX values obtained with PaO₂ might have been found more sensitive and specific in this study.

Previous studies investigating a correlation between SpO₂/FiO₂ and PaO₂/FiO₂ ratio found some differences supporting our results. Rice *et al.*, in their study to evaluate the SpO₂/FiO₂ ratio and PaO₂/FiO₂ ratio relationship for ARDS diagnosis, found that the SpO₂/FiO₂ ratio correlated well with simultaneously obtained PaO₂/FiO₂ ratios, but SpO₂/FiO₂ ratios of 235 and 315 were found to have corresponded to PaO₂/FiO₂ ratios of 200 and 300 respectively in ARDS patients [23]. In another study, researchers aimed to derive SpO₂/FiO₂ ratio correlations with the PaO₂/FiO₂ ratio to calculate the respiratory parameter of the SOFA score. There was a good correlation between the ratios in this study. Still, for the respiratory component of SOFA, corresponding PaO₂/FiO₂ and SpO₂/FiO₂ values for score one were <400 and <512, respectively, and for score 2, <300 and 357, respectively [8].

The ROX index was first described and validated in patients with hypoxemic respiratory failure and has been applied to predict the need for endotracheal intubation after HFNO application in patients with COVID-19. The ROX index has also been used to determine patients who may ultimately be weaned from HFNO. Results of these studies have shown that depending on the evaluation time or study, ROX values lower than 3 or 5 indicate HFNO failure and intubation indication [5,6]. In addition to its initial purpose, the ROX index was also applied to predict successful HFNO weaning.

Rodriguez *et al.* found that the ROX index was higher in the subjects who were successfully weaned from HFNO at the first trial than in those who failed (12.7 vs. 10.2, $p=0.002$) [24]. In another retrospective study conducted in the medical-surgical ICU, ROX after 8 hours of treatment was one of the best predictors of HFNO success (ROX>5.98 was associated with a lower risk of MV) [25]. Limited data reported values of the ROX index for weaning failure and EF exist. In a recent study, Filho *et al.* reported a 6.36 cut-off value for the prediction of EF. In this study, the authors reported that they calculated the ROX index during the extubation process, probably during SBT, without any pressure [26]. This ROX value was also calculated with SpO₂. In our study, a ROX value lower than 11 calculated with PaO₂ on the third day of MV predicted worse outcomes, including NRW, SBT failure, EF, and mortality.

All these results show that cut-off points change according to when and why they are calculated, such as to predict intubation during HFNO treatment, low-flow O₂ treatment, or to predict EF. Using PaO₂, SpO₂, or SaO₂ may also change the cut-off value. While there are very few studies evaluating the ROX index for WF and EF, it is possible to find many studies that assessed the PaO₂/FiO₂ ratio for weaning and EF. In a recent study performed on patients with COVID-19, Guzzati *et al.* reported that while

PaO₂/FiO₂>300 decreased, the probability of EF, PaO₂/FiO₂<200, is an independent predictor for EF [27].

The number of patients with chronic respiratory failure (24%) and comorbidities (43% pulmonary, 26% cardiac) was higher in our study population, and their MV and weaning durations were longer. Prediction of WR is significant in patient populations like ours. Because of this, not surprisingly, weaning could have been tried in only 60% of the patients 69% of them were successful and extubated, but 43% of them failed and were reintubated within 5 days. ROX index predicted EF from the third day of MV with 81% sensitivity and 70% specificity. Several weaning parameters have been assessed and used in clinical studies, but they are not very sensitive or specific when considered individually [5,13]. The most common weaning parameters to consider when initiating the SBT are RSBI (RR/VT) measured over 1 minute in a spontaneously breathing patient on low-level PEEP only has a higher sensitivity of 97% and moderate specificity of 65% for predicting patients who will subsequently pass the SBT [6]. Minute ventilation (VT×RR) of less than 10 L per minute only correlates with a positive predictive value of 50% and a negative predictive value of 40%. These parameters are calculated during the weaning period, but in our study, we estimated the ROX index not only during the weaning period but also during the beginning of MV, and our results suggest that the ROX index can predict WR, SBT failure, and EF from the beginning of MV when it is calculated with PaO₂. Possible reasons for this may be that patients begin to recover on the third day of MV, their sedation and vasopressor needs decrease, and their respiratory drive begins to return to normal. The fact that ROX values calculated with PaO₂ are more valuable than those calculated with saturation may be because the oxyhemoglobin curve starts to plateau with decreasing affinity to oxygen. In other words, after 90% saturation, PaO₂ rises while saturation increases more slowly. This may also be caused by conditions such as metabolic acidosis due to renal failure or sepsis, which shifts this curve to the right and reduces the affinity of haemoglobin to oxygen.

Similar to our results in another study evaluating venous blood gas values, researchers found that reduction of venous oxygenation saturation (central venous oxygen saturation over 4.5%) after 30 minutes of the SBT in patients who failed their first SBT is an independent predictor of reintubation with a sensitivity of 88% and specificity of 95% [28]. Our results suggest that the ROX index calculated during MV and weaning has high sensitivity and specificity in identifying SBT failure (76% and 60%, respectively) and EF (81% and 70%, respectively) in respiratory failure. It may help select patients who are ready to wean and extubate. We identified ROX index cutoffs that may be useful in selecting patients who could be successfully weaned from MV and EF.

ROX index calculated during the early days of MV also predicted mortality in this study population. Similar to our results, Lee *et al.* found significant mortality prediction in septic patients, but our sensitivity and specificity values are higher than this study [29].

Limitations of the study

Our retrospective and observational study may have caused some problems in evaluating the WR status of the patients. If the number of patients in the study had been larger, we could have had more patients in the EF and ES groups. Since the study was single-center and included many patients with chronic respiratory failure and comorbidities, our cut-off values cannot be generalized for patients with acute respiratory failure and non-hypercapnic patients. Again, when comparing cut-off values with the results obtained in other studies, it should be taken into account that the ROX values

calculated during MV were obtained under specific inspiration and expiration pressure values.

Conclusions

The results of this study suggest that calculating the ROX index using SpO₂%, arterial blood sampling PaO₂, and SaO₂% values may also help predict the WR evaluation, SBT, ES, and mortality. Further studies with more patients are necessary to verify and standardise these results.

References

1. Stefan MS, Shieh MS, Pekow PS, et al. Epidemiology and outcomes of acute respiratory failure in the United States, 2001 to 2009: a national survey. *J Hosp Med* 2013;8:76-82.
2. Epstein SK, Ciubotaru RL. Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation. *Am J Respir Crit Care Med* 1998;158:489-93.
3. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818-24.
4. Demisselle J, Calzia E, Hartmann C, et al. Target arterial PO₂ according to the underlying pathology: a mini-review of the available data in mechanically ventilated patients. *Ann Intensive Care* 2021;11:88.
5. Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index. *J Crit Care* 2016;35:200-5.
6. Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. *Am J Respir Crit Care Med* 2019;199:1368-76.
7. Suliman LA, Abdelgawad TT, Farrag NS, Abdelwahab HW. Validity of ROX index in prediction of risk of intubation in patients with COVID-19 pneumonia. *Adv Respir Med* 2021;89:1-7.
8. Pandharipande PP, Shintani AK, Hagerman HE, et al. Derivation and validation of Spo₂/Fio₂ ratio to impute for Pao₂/Fio₂ ratio in the respiratory component of the Sequential Organ Failure Assessment score. *Crit Care Med* 2009;37:1317-21.
9. Van de Louw A, Cracco C, Cerf C, et al. Accuracy of pulse oximetry in the intensive care unit. *Intensive Care Med* 2001;27:1606-13.
10. Perkins GD, McAuley DF, Giles S, et al. Do changes in pulse oximeter oxygen saturation predict equivalent changes in arterial oxygen saturation?. *Crit Care* 2003;7:R67-71.
11. Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. *Chest* 1990;97:1420-25.
12. Coplin WM, Pierson DJ, Cooley KD, et al. Implications of extubation delay in brain-injured patients meeting standard weaning criteria. *Am J Respir Crit Care Med* 2000;161:1530-36.
13. Macintyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians, the American Association for Respiratory Care, and the American College of Critical Care Medicine. *Chest* 2001;120:375S-95S.
14. Akella P, Voigt LP, Chawla S. To wean or not to wean: a practical patient focused guide to ventilator weaning. *J Intensive Care Med* 2022;37:1417-25.
15. Haas CF, Loik PS. Ventilator discontinuation protocols. *Respir Care* 2012;57:1649-62.
16. Nemer SN, Barbas CS. Predictive parameters for weaning from mechanical ventilation. *J Bras Pneumol* 2011;37:669-79.
17. Boles JM, Bion J, Connors A, et al. Weaning from mechanical ventilation. *Eur Respir J* 2007;29:1033-56.
18. Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. *N Engl J Med* 1995;332:345-50.
19. Vallverdú I, Calaf N, Subirana M, et al. Clinical characteristics, respiratory functional parameters, and outcome of a two-hour T-piece trial in patients weaning from mechanical ventilation. *Am J Respir Crit Care Med* 1998;158:1855-62.
20. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301-8.
21. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998;338:347-54.
22. Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2024;209:37-47.
23. Rice TW, Wheeler AP, Bernard GR, et al. Comparison of the Spo₂/Fio₂ ratio and the PaO₂/Fio₂ ratio in patients with acute lung injury or ARDS. *Chest* 2007;132:410-17.
24. Rodriguez M, Thille AW, Boissier F, et al. Predictors of successful separation from high-flow nasal oxygen therapy in patients with acute respiratory failure: a retrospective monocenter study. *Ann Intensive Care* 2019;9:101.
25. Artacho Ruiz R, Artacho Jurado B, Caballero Güeto F, et al. Predictors of success of high-flow nasal cannula in the treatment of acute hypoxemic respiratory failure. *Med Intensiva* 2021;45:80-7.
26. Andrade Filho PH, Brasil ESA, Costa LG, et al. Prediction of extubation failure in COVID-19. *Respir Care* 2021;66:1323-29.
27. Guzatti NG, Klein F, Oliveira JA, et al. Predictive factors of extubation failure in COVID-19 mechanically ventilated patients. *J Intensive Care Med* 2022;37:1250-55.
28. Jubran A, Mathru M, Dries D, Tobin MJ. Continuous recordings of mixed venous oxygen saturation during weaning from mechanical ventilation and the ramifications thereof. *Am J Respir Crit Care Med* 1998;158:1763-69.
29. Lee CU, Jo YH, Lee JH, et al. The index of oxygenation to respiratory rate as a prognostic factor for mortality in Sepsis. *Am J Emerg Med* 2021;45:426-32.